Primary source: Flowchart: Should I make a barring referral?
The removal of the supervision exemption for regulated activity with children will come into effect on September 1, 2026, and applies to England, Wales, and Northern Ireland.
This change affects compliance and safety obligations regarding activities with children, requiring organisations to adapt their checking processes and related policies.
Organisations should review their DBS checking arrangements, especially prioritizing checks that include the Children's Barred List for those working with children, as part of their compliance with the new definition from September 2026.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Organisations should review their DBS checking arrangements, especially prioritizing checks that include the Children's Barred List for those working with children, as part of their compliance with the new definition from September 2026.
Starting September 1, 2026, the definition of regulated activity with children will change, impacting how organisations assess their roles and whether DBS checks are necessary. Clarifications include the applicability of the change across different regions and settings.
What changed: The removal of the supervision exemption for regulated activity with children will come into effect on September 1, 2026, and applies to England, Wales, and Northern Ireland.
Why it matters: This change affects compliance and safety obligations regarding activities with children, requiring organisations to adapt their checking processes and related policies.
Practical implication: Organisations should review their DBS checking arrangements, especially prioritizing checks that include the Children's Barred List for those working with children, as part of their compliance with the new definition from September 2026.
Published from the regulator source ingestion pipeline after PV impact triage.
Submit bluetongue samples to APHA with forms attached securely on the outside of the parcel to facilitate rapid booking into their digital sample handling system.
Healthcare providers and manufacturers must now comply with new reporting obligations for adverse reactions associated with the use of Imaavy and ensure adherence to increased compliance requirements for its administration.
Regulatory intelligence teams should review ongoing studies and compliance with postmarketing requirements for the drugs listed, specifically focusing on their deadlines for completion and the nature of the studies required.
Stakeholders should incorporate the device authorization into labeling and signal management protocols to ensure compliance and effective communication regarding its capabilities.
